Procter & Gamble Health Limited Stock NSE India S.E.

Equities

PGHL

INE199A01012

Pharmaceuticals

End-of-day quote NSE India S.E. 06:00:00 2024-04-29 pm EDT 5-day change 1st Jan Change
4,910 INR +2.83% Intraday chart for Procter & Gamble Health Limited +4.44% -0.77%
Sales 2022 11.14B 134M Sales 2023 12.3B 147M Capitalization 87.13B 1.04B
Net income 2022 1.92B 23.07M Net income 2023 2.3B 27.5M EV / Sales 2022 5.95 x
Net cash position 2022 3.17B 37.93M Net cash position 2023 4.23B 50.69M EV / Sales 2023 6.74 x
P/E ratio 2022
36.1 x
P/E ratio 2023
38 x
Employees 1,407
Yield 2022
1.25%
Yield 2023
1.81%
Free-Float 47.83%
More Fundamentals * Assessed data
Dynamic Chart
Procter & Gamble Health Limited Declares Interim Dividend for the Financial Year 2023-24, Payable on or Before March 3, 2024 CI
Procter & Gamble Health Limited Declares Special Dividend for the Financial Year 2023-24, Payable on or Before March 3, 2024 CI
Procter & Gamble Health Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Procter & Gamble Health Limited Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Procter & Gamble Hygiene to Discontinue Injection Production at Goa, Unit, India MT
Procter & Gamble Health Limited Discontinues Production of Injections at its Manufacturing Plant in Goa Effective September 30, 2023 CI
Procter & Gamble Health's Net Profit Slumps in Fiscal Q4; Shares Dip 5% MT
Procter & Gamble Health Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Procter & Gamble Health Limited Reports Earnings Results for the Fourth Quarter Ended June 30, 2023 CI
Procter & Gamble Health Limited Recommends Final Dividend,Payable Between November 28, 2023 to December 18, 2023 CI
Procter & Gamble Health Limited Announces Change in Senior Management Personnel CI
Procter & Gamble India to invest $244 million to set up manufacturing facility RE
Procter & Gamble Health Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023 CI
Procter & Gamble Health Appoints CFO MT
Procter & Gamble Health Limited Appoints Lokesh Chandak as Chief Financial Officer, Effective April 1, 2023 CI
More news
1 day+2.83%
1 week+4.44%
Current month+4.24%
1 month+4.24%
3 months-5.12%
6 months-3.16%
Current year-0.77%
More quotes
1 week
4 636.55
Extreme 4636.55
4 988.75
1 month
4 636.55
Extreme 4636.55
4 988.75
Current year
4 636.55
Extreme 4636.55
5 642.85
1 year
4 575.00
Extreme 4575
5 642.85
3 years
3 870.10
Extreme 3870.1
6 429.00
5 years
2 891.45
Extreme 2891.45
7 500.00
10 years
611.05
Extreme 611.05
7 500.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 18-03-31
Director of Finance/CFO - 23-03-31
Compliance Officer - 21-06-30
Members of the board TitleAgeSince
Chairman 86 84-01-16
Director/Board Member 66 21-11-14
Director/Board Member 75 15-02-04
More insiders
Date Price Change Volume
24-04-30 4,910 +2.83% 23,164
24-04-29 4,775 +0.84% 9,061
24-04-26 4,735 +0.30% 4,362
24-04-25 4,721 -0.18% 11,382
24-04-24 4,729 +0.06% 3,971

End-of-day quote NSE India S.E., April 29, 2024

More quotes
Procter & Gamble Health Limited is an India-based company that is primarily engaged in the manufacturing of pharmaceutical products. The Company is engaged in the manufacturing and marketing of over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle. The Company’s brands include Cosome, Evion, Neurobion, Seven Seas, Nasivion, Polybion, and Livogen. Cosome is a medicine which is used to help relieve dry coughs and related congestion symptoms. Evion is a Vitamin E capsules. The Evion range has different variants with different levels of Vitamin E, such as Evion 400, Evion 200, and Evion 600. Neurobion offers a range of neurotropic B-Vitamins which are a combination to help treat nerve damage and regenerate the nerves to relieve symptoms. Nasivion Classic Nasal Spray starts working on a blocked nose in 25 seconds. Polybion is a brand that helps with release and hence supports an active life.
More about the company

Annual profits - Rate of surprise